BioSpace News Archive

Genetown

Vericel to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO will present at the 42nd Annual J.P. Morgan Healthcare Conference.

January 3, 2024
·
1 min read
Business

ENSEM Expands its Leadership Team with the Appointment of Jeff Kutok, M.D., Ph.D. as Chief Scientific Officer

Ensem Therapeutics Inc., a biotechnology company focusing on high value and difficult-to-drug oncology targets, today announced the appointment of Dr. Jeff Kutok as Chief Scientific Officer, effectively immediately.

January 3, 2024
·
3 min read
Biotech Bay

Enable Biosciences Inc. Reveals Key Findings on COVID-19 Transmission from Mothers to Newborns

Enable Biosciences Inc. has achieved a breakthrough in understanding maternal SARS-CoV-2 infection and its impact on newborns.

January 3, 2024
·
2 min read
Biotech Bay

Outset Medical to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Outset Medical, Inc. (Nasdaq: OM) (“Outset”) today announced that members of management will present at the 42nd annual J.P. Morgan Healthcare conference on Monday, January 8, 2024, at 5:15 p.m. Pacific time.

January 3, 2024
·
1 min read
Business

Medytox, Inc. Announces the Formation of Luvantas Subsidiary and Appointment of Key Executives

Medytox, Inc. is pleased to announce the formation of Luvantas, Inc. as its wholly-owned North American subsidiary.

January 3, 2024
·
3 min read
Drug Development

MAPLIGHT THERAPEUTICS ANNOUNCES COMPLETION OF PHASE 1 CLINICAL TRIAL FOR NOVEL M1/M4 MUSCARINIC AGONIST IN DEVELOPMENT FOR SCHIZOPHRENIA AND ALZHEIMER’S DISEASE PSYCHOSIS

MapLight Therapeutics today announced completion of a Phase 1 clinical trial evaluating the bioavailability, safety, and tolerability of an extended release formulation of ML-007, a novel M1/M4 preferring muscarinic agonist, alone and when co-administered with a precision-matched muscarinic antagonist designed to offset peripheral effects.

January 3, 2024
·
5 min read
Biotech Beach

SpineX Announces Successful in-Human Results to Treat Adults with Cerebral Palsy

SpineX Inc. today announced groundbreaking results in its first in-human study treating an adult with Cerebral Palsy (CP).

January 3, 2024
·
2 min read
Business

MediKarma and Arkos Health Enter Strategic Partnership to Support Patients to Better Manage Their Health and Improve Chronic Conditions

MediKarma today announced that the company has recently entered into a strategic partnership with Arkos Health. On December 1st 2023, the two organizations launched a six-month value-based care pilot program with the goal of generating healthier outcomes for individuals using MediKarma’s patient learning and engagement platform.

January 3, 2024
·
4 min read
Business

Better Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United States

Better Therapeutics Inc. and Glooko, Inc. today announced a partnership to integrate Better Therapeutics’ AspyreRx ™ digital behavioral treatment for type 2 diabetes (T2D) into Glooko’s diabetes management platform.

January 3, 2024
·
6 min read
FDA Grants Breakthrough Device Designation for Geneseeq’s Multi-cancer Early Detection Solution

Geneseeq announced that its multi-cancer early detection solution, CanScan™, has been granted Breakthrough Device Designation by the US Food and Drug Administration (FDA).

January 3, 2024
·
1 min read